Clinical Trial Update: Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing liposomal irinotecan plus 5-FU/leucovorin versus capecitabine in biliary tract cancer patients with recurrence after surgical resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Capecitabine (capecitabine)
• Leucovorin (folinic acid)
• Liposomal irinotecan (liposomal irinotecan)

Snippet

Sponsor: Sir Run Run Shaw Hospital | Conditions: Biliary Tract Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING